Market Overview

Oppenheimer Raises Sarepta's Target From $60 To $76

Related SRPT
Payor Re-Evaluation On Exondys Positive For Sarepta
Adam Feuerstein Weighs In On Novo-GBT Rumors, Undue Sarepta Volatility, Unprofitable Business Of Curing Disease

Shares of Sarepta Therapeutics Inc (NASDAQ: SRPT) have nearly doubled Monday, up 87 percent after the U.S. Food And Drug Administration accelerated approval for its Duchenne Muscular Dystrophy (DMD) drug, Eteplirsen.

The drug is the first of its kind to fight this rare disease, which typically kills patients before the age of 30.

Related Link: Sarepta's Eteplirsen Receives Accelerated FDA Approval, Shares Soar 80%

Oppenheimer reiterated its Outperform Rating on Sarepta and raised its 12-18 month price target from $60 to $76.

"Eteplirsen's approval is in line with our expectations, though the label is more inclusive than we had anticipated," the firm said. "We anticipate eteplirsen revenues to begin in 4Q16 and update our launch estimates to reflect label, post-marketing requirements, and launch delay. Sarepta will also receive a Rare Pediatric Disease Priority Review voucher, which could be worth up to $350M. We continue to model a 4Q16 financing to support launch."

The stock traded recently at $53.13, up 88 percent.

Latest Ratings for SRPT

Mar 2017NomuraInitiates Coverage OnBuy
Mar 2017Leerink SwannUpgradesMarket PerformOutperform
Dec 2016JP MorganInitiates Coverage OnOverweight

View More Analyst Ratings for SRPT
View the Latest Analyst Ratings

Posted-In: eteplirsen OppenheimerAnalyst Color News Price Target Reiteration FDA Analyst Ratings


Related Articles (SRPT)

View Comments and Join the Discussion!